AbCellera Biologics

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Executive Officer, and President of AbCellera, and other senior leaders (collectively, the “Selling Shareholders”), have entered into separate share purchase agreements with experienced institutional investors (the “Buyers”), pursuant to which the Buyers purchased an aggregate 11,900,000 common share

AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares

I recommended AbCellera on March 8, 2021, and so far the stock has gone pretty much nowhere. However, I am as bullish as ever. Immediate catalysts are lacking, but that does not preclude you from accumulating this stock at a reasonable valuation before the fireworks start.

AbCellera Biologics: My Highest Conviction Pick, With The Longest Potential Payoff

The stock price of AbCellera (Nasdaq: ABCL) increased by over 7% during intraday trading this morning. This is why it happened.

AbCellera (ABCL) Stock: Over 7% Increase Explanation

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Reports Q1 2021 Business Results

CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results

AbCellera stock tumbled Friday, despite in-line royalties for its Lilly-partnered Covid drug. Here's why the stock toppled.

Why AbCellera Stock Crumbled Despite In-Line Royalties For Covid Drug

AbCellera Biologics Inc. (ABCL) CEO Carl Hansen on Q1 2021 Results - Earnings Call Transcript

AbCellera Reports Q1 2021 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Present Virtually at Berenberg Conference on May 18, 2021

AbCellera to Present Virtually at Berenberg Conference on May 18, 2021

VANCOUVER, British Columbia & INNSBRUCK, Austria--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy

AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy

Eli Lilly

AbCellera Biologics Inc (NASDAQ: ABCL) has announced that a second antibody from its collaboration with Eli Lilly and Co (NYSE: LLY), LY-CoV1404, has entered clinical trials in patients with mild-to-moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trials to evaluate LY-CoV1404 alone and together with other monoclonal antibodies.

AbCellera-Lilly Partnered Second COVID-19 Antibody Enters Human Trials

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials

New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials

VANCOUVER, Canada--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals.

AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021

AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021

VANCOUVER, British Columbia & SAN DIEGO--(BUSINESS WIRE)---- $ABCL--AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration

AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present Virtually at Upcoming Investor Conferences

AbCellera to Present Virtually at Upcoming Investor Conferences

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--Published data show high potency of bamlanivimab against SARS-CoV-2 and support its clinical effectiveness to treat and prevent COVID-19.

Published Peer-Reviewed Data Demonstrate Bamlanivimab's High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19

Gilead Sciences

AbCellera Biologics Inc (NASDAQ: ABCL) has announced agreements to expand its collaboration with Gilead Sciences Inc (NASDAQ: GILD), including a multi-year, multi-target antibody discovery collaboration. Under the agreements' financial terms, AbCellera will receive an upfront payment and is eligible for milestone payments and royalties.

AbCellera, Gilead Ink New Multi-Target Antibody Discovery Collaboration

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration

AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration

The stock price of AbCellera Biologics Inc (NASDAQ: ABCL) has increased by over 10% pre-market. This is why it happened.

ABCL Stock Price Increased Over 10% Pre-Market: Why It Happened

AbCellera Biologics' (ABCL) CEO Carl Hansen on Q4 2020 Results - Earnings Call Transcript

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2020 Business Results

AbCellera Reports Full Year 2020 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalization and Prevented Death in Phase 3 Trial for Early COVID-19

AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19

AbCellera Biologics is a little followed and largely uncovered company. What it is building however is known all throughout the biotech and pharma industries. With the likes of Bill Gates, Peter Thiel and DARPA as key backers, AbCellera is quietly creating a call option on vast swaths of new and emerging biotech.

AbCellera Biologics: A Compounding Machine In Biotech Clothing

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #COVID19--EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients

EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera will present at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:20 p.m. Pacific Time.

News for AbCellera Biologics Stock (ABCL)